Clinical trials: Non Small Cell Lung Carcinoma NSCLC
Meningeal Metastasis
Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001
Phase Ib/II clinical study on evaluating the safety, tolerance, biodistribution characteristics and preliminary efficacy of recombinant human nsIL12 oncolytic adenovirus injection (BioTT001) in the treatment of meningeal…
- Trial name
- NCT07264569
- Testing
- BioTTT001 injection
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Henan Cancer Hospital
Non Small Cell Lung Cancer
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response.
- Trial name
- TroFuse-019 (NCT06312137)
- Testing
- Sacituzumab tirumotecan, Pembrolizumab, Cisplatin
- Where
- 270 sites in United States, Argentina and 29 more
- Volunteers
- 780 people
- Sponsor
- Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer
Assessment of Video Assisted Thoracoscopic Surgery (VATS) Versus Open Surgery for Patients Undergoing Lobectomy
Assessment of VATS versus standard open surgery for treatment of non small cell lung cancer.
- Trial name
- NCT00912366
- Testing
- Lobectomy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Medtronic - MITG
Neoplasms, Non-small-cell Lung Cancer
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
The purpose of this study is to learn about the: safety (the effect of the study medicine on the participant's body), effects of the study medicine alone or in combination with sasanlimab - the best amount of the study medicine.
- Conditions
- Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma
- Trial name
- NCT06546553
- Testing
- PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo)
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer
Early Palliative Care in Patients With Advanced Lung Cancer Using an e-Health Ecosystem
Palliative care has long been associated primarily with end-of-life support. However, its scope is much broader. As highlighted in the Hastings Center Report, the purposes of medicine include not only curing disease but also…
- Trial name
- AIRPAL (NCT07039994)
- Testing
- Standard intervention, E-health intervention
- Where
- 2 sites in Spain
- Volunteers
- 200 people
- Sponsor
- Jesús González
Non Small Cell Lung Cancer
Texture Features and PDL1 in CT-PET 18 FDG
Search correlation between texture features in CT-PET 18 FDG and overexpression of PDL1 in non-small cell lung carcinomas during the inital staging.
- Trial name
- NCT04309422
- Where
- France
- Volunteers
- 84 people
- Sponsor
- University Hospital, Montpellier
Carcinoma, Non-Small-Cell Lung
Efficacy Study of Induction Chemotherapy Before Surgery in Operable Non-small Cell Lung Cancer
This study is randomized phase III trial designed to assess whether (preoperative) neoadjuvant chemotherapy followed by surgery plus adjuvant chemotherapy with gemcitabine and cisplatin (experimental treatment) improves 3-year…
- Trial name
- NCT00329472
- Testing
- gemcitabine, cisplatin
- Sponsor
- Samsung Medical Center
Nonsmall Cell Lung Cancer Stage III
Multidisciplinary Treatment of Stage III ALK+ NSCLC With Neoadjuvant Alectinib and Chemotherapy
This is a multicenter, phase 2 non-randomized study to investigate the clinical feasibility and therapeutic efficacy of employing a MDT-based strategy in unresectable stage III ALK positive NSCLC following neoadjuvant alectinib…
- Trial name
- NCT07573696
- Testing
- After neoadjuvant alpelisib combined with chemotherapy, a multidisciplinary decision was made
- Volunteers
- 50 people
- Sponsor
- Wen-zhao ZHONG
Advanced Cancer, Metastatic Melanoma
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.
- Conditions
- Advanced Cancer, Metastatic Melanoma, Metastatic Non-small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT02857270
- Testing
- LY3214996, Midazolam, Abemaciclib
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 210 people
- Sponsor
- Eli Lilly and Company
Large Cell Lung Carcinoma, Lung Adenocarcinoma
Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
This randomized phase II trial studies how well carboplatin, paclitaxel, and bevacizumab (CPB) work when given with or without cixutumumab in treating patients with non-small cell lung cancer that is stage IV or has come back…
- Conditions
- Large Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
- Trial name
- NCT00955305
- Testing
- Bevacizumab, Carboplatin, Cixutumumab
- Where
- 165 sites in United States
- Volunteers
- 175 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Non-small Cell Lung Cancer (NSCLC)
AMT-116 in Combination With AK112 in Patients With Lung Cancer
The purpose of this study is to evaluate the safety and efficacy of AMT-116 in combination with Ivonescimab (AK112) in patients with advanced non-small cell lung cancer (NSCLC).
- Trial name
- NCT07590531
- Testing
- AMT-116, AK112
- Where
- 2 sites in China
- Volunteers
- 118 people
- Sponsor
- Multitude Therapeutics Inc.
Carcinoma, Non-Small-Cell Lung
Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population
This trial is an extension to ENSURE, a study of erlotinib versus gemcitabine/cisplatin combination chemotherapy as the first-line treatment for patients with non-small-cell lung cancer (NSCLC) with mutations in the tyrosine…
- Trial name
- NCT02000531
- Testing
- Erlotinib, Chemotherapy
- Where
- 11 sites in China
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung, Thoracic Surgery, Video-Assisted
VATS Lobectomy for Clinical Stage IB or II Lung Cancer
To examine the feasibility of VATS lobectomy for clinical stage IB or II non-small cell lung cancer. Success is defined as VATS lobectomy without conversion.
- Trial name
- NCT00425022
- Testing
- thoracoscopy
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- National Cancer Center, Korea
HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
The goal of this clinical trial is to test ELVN-002 in people with cancers that have an abnormal HER2 gene. The main question the trial aims to answer is if ELVN-002 is safe and tolerable at different doses.
- Conditions
- HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
- Trial name
- HER2 (NCT05650879)
- Testing
- ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Trastuzumab emtansine
- Where
- 39 sites in United States, Australia and 5 more
- Volunteers
- 198 people
- Sponsor
- Enliven Therapeutics
Non-Squamous Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
This 2 arm study will compare the efficacy and safety of sequential treatment with Tarceva or placebo, plus platinum-based therapy, as first line treatment in patients with advanced or recurrent non-small cell lung cancer.
- Trial name
- NCT00883779
- Testing
- Platinum chemotherapy (cisplatin or carboplatin), erlotinib [Tarceva], gemcitabine
- Where
- 26 sites in China, Hong Kong and 5 more
- Volunteers
- 451 people
- Sponsor
- Hoffmann-La Roche
Leptomeningeal Neoplasm, Metastatic Lung Non-Small Cell Carcinoma
Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer
This phase I/Ib trial studies the side effects and best dose of CB-839 HCl when given together with sapanisertib in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced).
- Conditions
- Leptomeningeal Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Lung Non-Small Cell Carcinoma
- Trial name
- NCT04250545
- Testing
- Sapanisertib, Telaglenastat Hydrochloride
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH)
This is an open-label, multi-center, randomized, phase III study. It is aimed to firstly evaluate the effectiveness and safety of almonertinib induction therapy in EGFR-mutated patients with unresectable stage III non-small cell…
- Trial name
- APPROACH (NCT04841811)
- Testing
- Almonertinib
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Guangdong Association of Clinical Trials
Lung Adenocarcinoma, Stage III Lung Cancer
Firmonertinib Plus Chemotherapy for Unresectable EGFR PACC-Mutant Stage III Lung Cancer: A Phase II Study
This is a prospective, single-arm, multicenter Phase II clinical study. It aims to evaluate the efficacy and safety of Firmonertinib combined with chemotherapy in patients with unresectable Stage III lung adenocarcinoma harboring…
- Conditions
- Lung Adenocarcinoma, Stage III Lung Cancer, EGFR Positive Non-small Cell Lung Cancer
- Trial name
- NCT07878871
- Testing
- Firmonertinib, Platinum-based chemotherapy
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Hunan Province Tumor Hospital
Pneumonitis, Nonsmall Cell Lung Cancer Stage III
Exhaled Breath Analysis to Predict Risk of Symptomatic Pneumonitis
This is a prospective pilot study investigating exhaled breath condensate analyses to quantify the variability over time of various biomarkers associated with symptomatic pneumonitis.
- Trial name
- NCT04040244
- Testing
- Exhaled Breath Collection, Blood sample
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Wake Forest University Health Sciences
Non-small-cell Lung Cancer
Functional Imaging of Treatment Effects: A Companion Protocol to a Study of Extracranial Stereotactic Radioablation in Early Stage Non-Small Cell Lung Cancer
For this companion protocol, we intend to make an assessment of both tumor response and local tissue effects. Patients undergoing the correlative investigation will be a subset of the patients already enrolled on the phase II…
- Trial name
- SBF Companion (NCT00246116)
- Testing
- Functional Imaging of Treatment Effects
- Volunteers
- 15 people
- Sponsor
- Indiana University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.